 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
0 News |  |
- resolvin E1 (TP-317) / Thetis Pharma
TP-317, a Novel BLT1 Agonist Oral Therapy for Inflammatory Bowel Disease, Exhibits Anti-Inflammatory and Epithelial Barrier Protective Efficacy in Murine DSS Colitis and TNF?ARE Ileitis (Poster exhibition) - Jan 11, 2025 - Abstract #ECCOIBD2025ECCO_IBD_1378;
Methods DSS colitis : 8-wk old C57Bl6/J mice (n=12/group) were given two 5-day cycles of DSS (1%, 2%) separated by a 10-day recovery period, followed by 7 days of daily oral treatment starting on day 20 with TP-317 (0.04, 0.4 or 4 mg/kg), cyclosporin (25 mg/kg), the JAK1 inhibitor filgotinib (36 mg/kg), or vehicle. These findings align with reports of have exacerbated DSS colitis in BLT1-/- mice and RvE1
- resolvin E1 (TP-317) / Thetis Pharma
Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Oral Resolvin E1-based Therapy in Inflammatory Bowel Disease (IBD): Translating Resolvin E1 Activation of BLT1 in Experimental Models to Healthy Volunteers (Poster exhibition) - Dec 21, 2024 - Abstract #ECCOIBD2025ECCO_IBD_982;
Transient neutropenia observed with TP-317, a known effect of BLT1 activation by LTB4 and RvE1, suggests target engagement in humans. Oral TP-317
- | resolvin E1 (TP-317) / Thetis Pharma
Preclinical, Journal: ATP citrate lyase (ACLY)-dependent immunometabolism in mucosal T cells drives experimental colitis in vivo. (Pubmed Central) - Mar 11, 2024
ACLY controls mucosal T cell immunometabolism and experimental colitis. Therapeutic modulation of ACLY expression in T cells emerges as a novel strategy to promote the resolution of intestinal inflammation.
- | resolvin E1 (TP-317) / Thetis Pharma
Preclinical, Journal: Chemokine?like receptor 1?positive cells are present in the odontoblast layer in tooth tissue in rats and humans. (Pubmed Central) - Jan 24, 2024
Following treatment of dental pulp stem cells with lipoteichoic acid, which imitates Gram-positive bacterial infection, resolvin E1 did not suppress the expression of cyclooxygenase-2 or of the odontoblast differentiation marker, dentin sialophosphoprotein. Furthermore, resolvin E1 induced the differentiation of dental pulp stem cells into odontoblasts even in the presence of the inflammatory stimulus.
- resolvin E1 (TP-317) / Thetis Pharma
The Effect of Resolvin E1 and Resolvin D1 Specialised Pro-resolving Mediators on the Inhibition of Osteoclastogenesis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3720;
In summary, this study highlights the capacity of RvE1 and RvD1 to specifically modulate OC differentiation in primary human cells in either health or RA. Combined, these findings suggest a potential for SPMs as novel treatment for RA.
- | naproxen / Generic mfg.
Preclinical, Journal: Combination of Naproxen and a Chemically-Stable Eicosapentaenoic Acid Analogue Provide Additive Tumor Protection in Pirc rats. (Pubmed Central) - Apr 17, 2023
A comprehensive lipidomic analysis also uncovered several potential pharmacodynamic (PD) lipid biomarkers, including resolvin E2, 9-HEPE, 12-HEPE and 18-HEPE, that were significantly correlated with tumor protection. Further studies with this drug combination should be focused on dose optimization and the role of EPA-derived lipid mediators in CRC initiation and progression.